Português
EnglishOn April 27, Innovent Biologics, Inc. and DingTalk officially signed a framework cooperation agreement, marking the transition of their collaboration from office collaboration to a new stage of artificial intelligence applications. This partnership will focus on advancing the "Wukong" pilot program, helping Innovent Biologics revolutionize its work model in the AI era. At the signing ceremony, Dr. Yu Dechao, founder, chairman of the board, and CEO of Innovent Biologics, along with Chen Hang, founder of DingTalk and "Wukong," were present to witness and complete the signing of the agreement.
Innovation Leads Development, Global Strategic Layout
As a leading innovative biopharmaceutical company in China and a national high-tech enterprise, Innovent Biologics focuses on the research, development, manufacturing, and commercialization of innovative drugs for major diseases such as cancer, autoimmune disorders, metabolic diseases, and ophthalmology. Its core product in the metabolic field, Mashi Duopeptide, is the world's first and currently only approved natural dual-target GCG/GLP-1 drug, offering both weight-loss and blood-sugar-lowering benefits, along with remarkable fat-burning and liver-protecting effects, potentially providing breakthrough treatment options for hundreds of millions of patients with metabolic disorders. Currently, the company is accelerating its long-term strategy of "innovation-driven globalization" through an end-to-end intelligent manufacturing system and a globally synchronized R&D network.
Deepening AI Collaboration, Advancing Smart Healthcare
The biopharmaceutical industry demands high levels of efficiency, compliance, and continuous innovation. Although the threshold for applying AI technology remains relatively high, it has become an indispensable driver of transformation. In the past, Innovent Biologics partnered with DingTalk to create the dedicated mobile office platform "XindaDing," laying a solid foundation for the company's digital transformation. Faced with intensifying industry competition and the rapid evolution of AI technologies, Innovent Biologics has further clarified its AI development roadmap. This upgraded collaboration will deeply integrate the AI capabilities of DingTalk and "Wukong," providing comprehensive intelligent support to all employees and enhancing organizational operational efficiency.
Dr. Yu Dechao stated: "I have enjoyed seamless cooperation with DingTalk for many years, and 'XindaDing' has long been the core platform for our team's daily collaboration. As DingTalk—especially 'Wukong'—continuously strengthens its AI features, we believe this will provide powerful tools to help Innovent fully embrace AI technology. At the same time, we hope that through this collaboration, we can jointly develop application scenarios tailored to the biopharmaceutical industry, creating value for the entire sector."
Collaboratively Building an AI Ecosystem, Exploring Agent Applications
Based on their shared strategic vision, both parties will strengthen cooperation in areas such as optimizing the AI collaboration platform and co-building business scenarios, accelerating the practical implementation of Innovent Biologics' AI strategy.
In terms of foundational AI infrastructure, they will center on "XindaDing," integrating flagship AI features like AI note-taking and AI spreadsheets to comprehensively boost productivity. On the talent development and joint innovation fronts, they will roll out tiered AI training programs covering all employees and cultivate an internal AI vanguard through AI boot camps and innovation competitions. Additionally, they will establish a joint AI innovation lab focused on incubating high-value biopharmaceutical AI solutions.
Building on this foundation, both sides will actively promote the pilot deployment of "Wukong" within the company, extending its reach across various business scenarios. Leveraging "Wukong's" technological strengths, Innovent Biologics will pioneer a corporate-level AI agent pilot project, evaluating the feasibility and benefits of AI agents handling high-frequency, repetitive tasks, with a focus on safety-compliance reviews and human-machine collaboration models.
This collaboration represents not only an upgrade at the tool level but also a deep exploration of practical AI applications, aimed at helping Innovent Biologics build robust AI capabilities. Chen Hang noted: "Innovent Biologics is one of the few Chinese companies truly competitive on the global stage in the innovative pharmaceutical sector. We look forward to working with Innovent through this partnership to pioneer a new paradigm of pharmaceutical operations in the AI era, setting a benchmark for the digital transformation of the biopharmaceutical industry."
DomTech is DingTalk's official designated service provider in Macau, specializing in providing DingTalk services to a wide range of customers. If you'd like to learn more about DingTalk platform applications, feel free to consult our online customer service or contact us by phone at +852 95970612 or via email at [email protected]. With an outstanding development and operations team and extensive market service experience, we can offer you professional DingTalk solutions and services!